Cohance Lifesciences Ltd (NSE: COHANCE, BSE: 543064) is a Hyderabad, Telangana-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹17,754 Cr, it ranks #399 by market cap among the 6,137 Indian listed companies on FinBizNet, and #4 of 11 in Pharmaceutical CDMO and CRO Services. At ₹449.85 (as of 25 Oct 2026), the share price is 48.6% below its 52-week high of ₹875.00 and 68.7% above its 52-week low of ₹266.70. The share price is down 49.9% over one year and up 7.9% over three months.
| Current Price | ₹449.85 |
|---|---|
| Market Cap | ₹17,754 Cr |
| NSE Symbol | COHANCE |
| BSE Code | 543064 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 97.9 |
| Return on Equity | 5.11% |
| Return on Assets | 2.69% |
| 52-Week Range | ₹266.70 – ₹875.00 |
| 1-Year Price Change | -49.9% |
| 3-Month Price Change | +7.9% |
| Beta (1Y) | 0.34 |
| Dividend Yield | 0.00% |
| Headquarters | Hyderabad, Telangana |
| Website | www.cohance.com |
| Revenue | ₹422 Cr |
|---|---|
| Net Profit | ₹-45 Cr |
| Net Margin | -10.7% |
| EPS (Basic) | ₹-0.63 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
1. Contract Development and Manufacturing Operations (CDMO)-This segment develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services. 2. NA-NA 3. NA-NA 4. NA-NA
1. Contract Development and Manufacturing Operations (CDMO)-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹2,42,758 Cr | 93.8 | 16.19% | ₹3,080 Cr | +35.6% |
| Anthem Biosciences Limited | ₹46,303 Cr | 77.5 | 19.45% | ₹418 Cr | +5.3% |
| Sai Life Sciences Limited | ₹29,513 Cr | 85 | 15.13% | ₹554 Cr | +58.5% |
| Cohance Lifesciences Ltd | ₹17,754 Cr | 97.9 | 5.11% | ₹422 Cr | -49.9% |
| Onesource Specialty Pharma Limited | ₹16,144 Cr | -213 | -1.26% | ₹449 Cr | -27.8% |
| Syngene International Ltd. | ₹15,371 Cr | 50.6 | 6.62% | ₹736 Cr | -42.7% |
| Jubilant Pharmova Ltd | ₹14,958 Cr | 37.3 | 5.96% | ₹2,229 Cr | -12.8% |
| Concord Biotech Ltd | ₹14,008 Cr | 51.7 | 13.54% | ₹257 Cr | -19.5% |
| Blue Jet Healthcare Ltd | ₹9,855 Cr | 35.5 | 19.88% | ₹293 Cr | -29.2% |
Listed by market capitalisation. Ratios are shown for context only.
Cohance Lifesciences Ltd is trading at ₹449.85, with a market capitalisation of ₹17,754 Cr.
Cohance Lifesciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Cohance Lifesciences Ltd has a P/E of 97.9 and a return on equity of 5.11%.
Cohance Lifesciences Ltd is listed on the NSE under the symbol COHANCE and on the BSE under the scrip code 543064.
Cohance Lifesciences Ltd's share price is down 49.9% over one year and up 7.9% over three months. Its 52-week range is ₹266.70 to ₹875.00.
In Q1 FY27, Cohance Lifesciences Ltd reported revenue of ₹422 Cr and net profit of ₹-45 Cr, with basic EPS of ₹-0.63 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.